Drug Search Results
More Filters [+]

Tigatuzumab

Alternative Names: tigatuzumab, cs-1008
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TNFS10B Agonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tigatuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Triple Negative Breast Cancer|Hepatocellular Carcinoma|Ovarian Cancer|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Adenocarcinoma

Phase 1: Oncology Unspecified|Colorectal Cancer|Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

F101004001 (UAB1028)

P2

Completed

Triple Negative Breast Cancer

2016-06-01

JapicCTI-101138

P2

Completed

Hepatocellular Carcinoma

2013-07-31

CS1008-A-U105

P1

Completed

Colorectal Cancer

2013-07-01

LUD2010-002

P1

Completed

Colorectal Cancer

2012-06-27

Recent News Events